Page 14 - Glenmark Pharmaceuticals

Glenmark drug for mild Covid patients hits market, priced at Rs 103 a pill

FabiFlu is generic version of oral antiviral favipiravir; almost 80% patients are mildly sick, market potential for the oral drug is huge

Favipiravir shows improvement in moderate Covid-19 cases: Glenmark

The domestic pharma giant announced the launch of the first oral Favipiravir in the brand name "FabiFlu" claiming that it is backed by strong clinical evidence

Glenmark launches Covid-19 drug FabiFlu, priced at Rs 103 per tablet

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement

Glenmark Pharma gets USFDA nod for drug to treat multiple sclerosis

The capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis

Glenmark to begin clinical trial in India to test Covid-19 drug combination

Drugmakers across the world have been rushing to develop a treatment or vaccine for the fast-spreading coronavirus, which has infected 5.5 million people globally, killing more than 345,000

Govt mulls faster drug approval process, regulatory system overhaul

The industry, which has been lobbying for faster approvals for quite some time now, says the current pandemic should help expedite the reforms process

Strides Pharma to conduct trials for potential Covid-19 drug Favipiravir

Favipiravir is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014

Mumbai docs want key drugs made available fast as hospital wards swell up

If patients recover faster, they needn't stay in hospital for 14 days and this could free up beds; Remdesivir and Favipiravir are in the process of being made available in India

Covid-19: Pune-based drug firm to export favipiravir to 18 countries

Favipiravir is under trial in many countries as a potential treatment for Covid-19

Top 10 biz headlines: RIL results, FMCG mkt to see 'slowest' growth & more

Here are the top 10 business headlines this morning

In race to stop Covid-19, Indian drugmakers to conduct clinical trials

Glenmark, Zydus Cadila to start trials in May

Glenmark gets DCGI nod for clinical trials of potential Covid-19 drug

As per the clinical trial protocol approved, 150 subjects with mild to moderate Covid-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care

Strong outlook, attractive valuations driving Glenmark's bounce back

US growth remains crucial for earnings upgrades, while licensing deals can help reduce both, costs and debt

Street positive in Hindustan Unilever's ability to scale up VWash

Strong distribution network and company's cost efficiency would help increase sales of the acquired high-margin portfolio

HUL zooms 10% after announcing acquisition of Vwash from Glenmark

Glenmark will manufacture VWash for HUL over the next one year after which the production arrangement would be reviewed

Glenmark gets tentative nod from USFDA for generic type-2 diabetes tablets

The product is a generic version of AstraZeneca AB's Farxiga tablets

More drug licensing deals will play a big part in paring Glenmark's debt

The company's US sales growth has remained subdued due to intense competition for its dermatology range.

Glenmark Pharma shines as September quarter marks rebound in earnings

Analysts are upgrading their ratings as they expect sales momentum in the US and domestic markets to improve

Glenmark Pharma net declines 38% to Rs 255.54 cr in September quarter

Glenmark's total expenses was at Rs 2,548.56 crore during the period as against Rs 2,308.80 crore, up 10.38%

New FDA warning letters show Indian drug makers' quality concerns persist

The latest regulatory crackdown shows US regulator's stance is hardening toward lapses in quality control even as it seeks cheaper drugs to contain health care costs